Back to Search
Start Over
Outcomes and risk factors of SARS‐CoV‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy.
- Source :
-
Cancer Medicine . Nov2023, Vol. 12 Issue 22, p20838-20846. 9p. - Publication Year :
- 2023
-
Abstract
- Background: Little was known on infection and mortality rates, still less the risk factors of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) omicron variant in B‐cell lymphoma patients following CD19 targeted chimeric antigen receptor T cell (CAR‐T). Aims: We performed a retrospective multicenter study and analyzed the details of relapsed/refractory (R/R) B‐cell lymphoma patients who received CD19 targeted CAR‐T heretofore in five cellular immunotherapy centers in China during the omicron wave. Materials & Methods: One hundred fifty‐four patients were enrolled in this study. Results: Among them, 52 patients (33.8%) were uninfected, 74 patients (48.1) had ambulatory mild disease (including nine patients of asymptomatic infection), 22 patients (14.3%) had moderate disease and six patients (3.9%) had severe disease when data collected up. Three patients with severe disease died from COVID‐19, the death rate was 1.9% for all enrolled patients, and 2.9% for infected patients. We also found that patients over 60 years old or with diabetes mellitus (DM) tend to develop severe disease (p = 0.0057 and p = 0.0497, respectively). Patients had CAR‐T infusion within 6 months also tend to have severe disease (p = 0.0011). In multivariate logistic regression model, CAR‐T infusion within 6 months (relative risk (RR) 40.92; confidence interval (CI) 4.03–415.89; p = 0.002) were associated with significantly higher risk of severe disease. Conclusion: Through this study, we conclude that the outcome for B‐cell lymphoma patients following CD19 targeted CAR‐T therapy when facing omicron infection was improved, but aggressive precautionary measures were particularly crucial for patients with high risk factors. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 12
- Issue :
- 22
- Database :
- Academic Search Index
- Journal :
- Cancer Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 174108100
- Full Text :
- https://doi.org/10.1002/cam4.6657